Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment

Patients with rheumatoid arthritis (RA) are at approximately 1.5-fold risk of atherosclerotic cardiovascular disease (CVD) compared with the general population, a phenomenon resulting from combined effects of traditional CVD risk factors and systemic inflammation. Rheumatoid synovitis and unstable a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anne Mirjam Kerola, Silvia Rollefstad, Anne Grete Semb
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/e08fa4ce7c8a4d51b25860323e4e554a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e08fa4ce7c8a4d51b25860323e4e554a
record_format	dspace
spelling	oai:doaj.org-article:e08fa4ce7c8a4d51b25860323e4e554a2021-12-04T16:04:28ZAtherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment10.15420/ecr.2020.441758-37641758-3756https://doaj.org/article/e08fa4ce7c8a4d51b25860323e4e554a2021-05-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2020.44https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Patients with rheumatoid arthritis (RA) are at approximately 1.5-fold risk of atherosclerotic cardiovascular disease (CVD) compared with the general population, a phenomenon resulting from combined effects of traditional CVD risk factors and systemic inflammation. Rheumatoid synovitis and unstable atherosclerotic plaques share common inflammatory mechanisms, such as expression of proinflammatory cytokines interleukin (IL)-1, tumour necrosis factor (TNF)-α and IL-6. RA patients are undertreated in terms of CVD prevention, and structured CVD prevention programmes are warranted. Alongside management of traditional risk factors, suppressing systemic inflammation with antirheumatic medication is fundamental for the reduction of CVD risk among this high-risk patient group. Many antirheumatic drugs, especially methotrexate, TNF-α-inhibitors and IL-6-inhibitors are associated with reduced risk of CVD in observational studies among RA patients, but randomised controlled trials with hard CVD endpoints are lacking. In patients without rheumatic disease, anti-inflammatory therapies targeting nucleotide-binding oligomerisation domain, leucine-rich repeat and pyrin domain-containing protein 3 inflammasome and the IL-1/IL-6 pathway arise as potential therapies after an atherosclerotic CVD event.Anne Mirjam KerolaSilvia RollefstadAnne Grete SembRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 16, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Anne Mirjam Kerola Silvia Rollefstad Anne Grete Semb Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
description	Patients with rheumatoid arthritis (RA) are at approximately 1.5-fold risk of atherosclerotic cardiovascular disease (CVD) compared with the general population, a phenomenon resulting from combined effects of traditional CVD risk factors and systemic inflammation. Rheumatoid synovitis and unstable atherosclerotic plaques share common inflammatory mechanisms, such as expression of proinflammatory cytokines interleukin (IL)-1, tumour necrosis factor (TNF)-α and IL-6. RA patients are undertreated in terms of CVD prevention, and structured CVD prevention programmes are warranted. Alongside management of traditional risk factors, suppressing systemic inflammation with antirheumatic medication is fundamental for the reduction of CVD risk among this high-risk patient group. Many antirheumatic drugs, especially methotrexate, TNF-α-inhibitors and IL-6-inhibitors are associated with reduced risk of CVD in observational studies among RA patients, but randomised controlled trials with hard CVD endpoints are lacking. In patients without rheumatic disease, anti-inflammatory therapies targeting nucleotide-binding oligomerisation domain, leucine-rich repeat and pyrin domain-containing protein 3 inflammasome and the IL-1/IL-6 pathway arise as potential therapies after an atherosclerotic CVD event.
format	article
author	Anne Mirjam Kerola Silvia Rollefstad Anne Grete Semb
author_facet	Anne Mirjam Kerola Silvia Rollefstad Anne Grete Semb
author_sort	Anne Mirjam Kerola
title	Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
title_short	Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
title_full	Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
title_fullStr	Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
title_full_unstemmed	Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
title_sort	atherosclerotic cardiovascular disease in rheumatoid arthritis: impact of inflammation and antirheumatic treatment
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/e08fa4ce7c8a4d51b25860323e4e554a
work_keys_str_mv	AT annemirjamkerola atheroscleroticcardiovasculardiseaseinrheumatoidarthritisimpactofinflammationandantirheumatictreatment AT silviarollefstad atheroscleroticcardiovasculardiseaseinrheumatoidarthritisimpactofinflammationandantirheumatictreatment AT annegretesemb atheroscleroticcardiovasculardiseaseinrheumatoidarthritisimpactofinflammationandantirheumatictreatment
_version_	1718372705847214080

Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment

Ejemplares similares